Amar U Kishan/X
Jun 12, 2025, 19:31
Amar Kishan: UCLA Launched ILLUSION Trial on 2 mm PTV Margins in CT-Guided SBRT
Amar Kishan, Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA, shared a post on X:
“Pleased to share great work out in IJROBP – The Red Journal from UCLA Jonsson Comprehensive Cancer PGY-4 Travis Courtney on possibilities with 2 mm PTV margins in CT-guided SBRT.
Briefly, while accepting that many decisions go into the decision on an acceptable PTV margin, we modeled the dosimetric outcomes had CT-guided SBRT patients on MIRAGE been treated with 2 mm PTV margins. We then used NTCP modeling to estimate potential toxicity impacts.
The dosimetric gains from reducing margins in the CT-guided SBRT group would be predicted to yield improved toxicity (at least rectal toxicity). Now the major question is — how tight can you go with CT-guided SBRT? That is, can these in silico margins be used in practice?
Time to put words to action -> we have opened the ILLUSION trial at UCLA Jonsson Comprehensive Cancer, exploring 2 mm PTV margins with prostate SBRT, leveraging either triggered imaging with automatic beam hold or adaptive SBRT. This is a Varian sponsored IIT.
More posts featuring Amar Kishan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 11:56
Jul 3, 2025, 11:29
Jul 3, 2025, 10:55
Jul 3, 2025, 10:25
Jul 3, 2025, 10:24
Jul 3, 2025, 10:16
Jul 3, 2025, 10:15